Gene therapy's big comeback
Elliott Sigal earned a reputation at Bristol-Myers Squibb as one of the drug industry's best research chiefs. His bets on risky technologies like cancer immunotherapy and new types of diabetes drugs helped Bristol turn from a laggard into a growth stock. But there was one technology he wouldn't touch: gene therapy, which tries to use engineered viruses to defeat disease at the DNA level.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063